126 related articles for article (PubMed ID: 17320202)
1. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation.
Gibbs L; Legeai-Mallet L
Biochim Biophys Acta; 2007 Apr; 1773(4):502-12. PubMed ID: 17320202
[TBL] [Abstract][Full Text] [Related]
2. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
3. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
4. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
5. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
6. The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling.
Lievens PM; Mutinelli C; Baynes D; Liboi E
J Biol Chem; 2004 Oct; 279(41):43254-60. PubMed ID: 15292251
[TBL] [Abstract][Full Text] [Related]
7. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
8. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
9. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
10. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia.
Pannier S; Couloigner V; Messaddeq N; Elmaleh-Bergès M; Munnich A; Romand R; Legeai-Mallet L
Biochim Biophys Acta; 2009 Feb; 1792(2):140-7. PubMed ID: 19073250
[TBL] [Abstract][Full Text] [Related]
11. Suppression of severe achondroplasia with developmental delay and acanthosis nigricans by the p.Thr651Pro mutation.
Manickam K; Donoghue DJ; Meyer AN; Snyder PJ; Prior TW
Am J Med Genet A; 2014 Jan; 164A(1):243-50. PubMed ID: 24352917
[TBL] [Abstract][Full Text] [Related]
12. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
[TBL] [Abstract][Full Text] [Related]
13. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.
He L; Serrano C; Niphadkar N; Shobnam N; Hristova K
PLoS One; 2012; 7(4):e34808. PubMed ID: 22529939
[TBL] [Abstract][Full Text] [Related]
14. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
15. Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.
Heuertz S; Le Merrer M; Zabel B; Wright M; Legeai-Mallet L; Cormier-Daire V; Gibbs L; Bonaventure J
Eur J Hum Genet; 2006 Dec; 14(12):1240-7. PubMed ID: 16912704
[TBL] [Abstract][Full Text] [Related]
16. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.
Guo C; Degnin CR; Laederich MB; Lunstrum GP; Holden P; Bihlmaier J; Krakow D; Cho YJ; Horton WA
Cell Signal; 2008 Aug; 20(8):1471-7. PubMed ID: 18485666
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
He L; Shobnam N; Wimley WC; Hristova K
J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
[TBL] [Abstract][Full Text] [Related]
18. Thanatophoric dysplasia caused by double missense FGFR3 mutations.
Pannier S; Martinovic J; Heuertz S; Delezoide AL; Munnich A; Schibler L; Serre V; Legeai-Mallet L
Am J Med Genet A; 2009 Jun; 149A(6):1296-301. PubMed ID: 19449430
[TBL] [Abstract][Full Text] [Related]
19. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
Tanaka H
Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
